Osaka, Kyoto, and Kobe—known as popular tourist destinations in Japan’s Kansai region— are also emerging as drug discovery hubs 💊. Kansai is becoming a key center in Japan’s drug discovery ecosystem, built on each city’s strengths. Learn more about its appeal and progress 👀
🌏 OBI recognized at ABEA 2026 for leadership in ADC innovation OBI Pharma was honored with “Best ADC Developer in Taiwan” at the Asia-Pacific Biopharma Excellence Awards (ABEA) 2026. 🔬
At the same ceremony, Dr. Heidi Wang, Chief Executive Officer of OBI, received the Women’s Leadership in ADC Development Award. 🏆
At ADC Asia Congress 2026, Dr. David Teng-Yi Huang also presented advances in GlycOBI® glycan-conjugation technologies supporting next-generation dual-payload ADC design.
#ADCAsiaCongress #ADCAsiaCongress2026 #ABEA2026 #IMAPAC #AsiaPacificBiopharmaExcellenceAwards
#ADC #AntibodyDrugConjugates #CancerResearch #PrecisionOncology #OBIPharma #GlycOBI
https://t.co/HwkKQJTl8w
OBI’s TROP2 ADC OBI-902 has been granted Orphan Drug Designation by the U.S. FDA for the treatment of cholangiocarcinoma, a rare and aggressive cancer with limited treatment options.
#OBIPharma#OBI902#ADC#OrphanDrugDesignation#Cholangiocarcinoma
https://t.co/nd2vwhLtxE
本日から福岡で開催される10th Modern Solid Phase Peptide Synthesis & Its Applications Symposium (#SPPS2025)にて企業展示に出展いたします。
皆様のお越しをお待ちしております!
↓イベント詳細↓
https://t.co/X79cmiMhPT